Form 4: Metagenomi's Chief Medical Officer Reports Acquisition of Shares and Stock Options

Chief Medical Officer of Metagenomi, Sarah B. Noonberg, reports acquisition of restricted stock units and stock options.

Summary

• On April 1, 2024, Sarah B. Noonberg, Chief Medical Officer of Metagenomi, Inc., acquired 57,763 shares of common stock in the form of restricted stock units (RSUs) and 242,875 stock options.
• The RSUs vest with 25% vesting on June 5, 2025, and the remainder in 12 equal quarterly installments thereafter, contingent upon continued service.
• The stock options vest with 25% vesting on April 1, 2025, and the remainder in 36 equal monthly installments thereafter, contingent upon continued service.
• Following these transactions, Noonberg directly owns 100,374 shares of common stock and 242,875 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a key executive suggests confidence in the company's prospects. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of RSUs and stock options by the Chief Medical Officer suggests confidence in the company's future performance.
• The vesting schedules for both RSUs and stock options incentivize continued service and commitment from the Chief Medical Officer.

Future Outlook

The vesting schedules for the RSUs and stock options suggest an expectation of continued service and contribution from the Chief Medical Officer over the next several years.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the ownership structure and incentives for key executives.

Stakeholder Impact

• The acquisition of shares and options by the Chief Medical Officer could positively influence shareholder confidence.

Key Dates